A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer.

Zhang, Qingyuan; Shao, Bin; Tong, Zhongsheng; Ouyang, Quchang; Wang, Yuting; Xu, Guoying; Li, Shaorong; Li, Huiping

Zhang, Qingyuan; Shao, Bin; Tong, Zhongsheng; Ouyang, Quchang; Wang, Yuting; Xu, Guoying; Li, Shaorong; Li, Huiping.

Afiliação

Zhang Q; Department of Breast Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Shao B; Department of Breast Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, No.52 Fucheng Road, Haidian District, Beijing, 100142, China.
Tong Z; Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Ouyang Q; Department of Breast Oncology, Hunan Cancer Hospital, Changsha, China.
Wang Y; Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co. Ltd., Shanghai, China.
Xu G; Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co. Ltd., Shanghai, China.
Li S; Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co. Ltd., Shanghai, China.
Li H; Department of Breast Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, No.52 Fucheng Road, Haidian District, Beijing, 100142, China. huipingli2012@hotmail.com.

BMC Med ; 20(1): 321, 2022 10 03.

Article em En | MEDLINE | ID: mdl-36184642

Assuntos

Neoplasias de Mama Triplo Negativas; Difosfato de Adenosina/uso terapêutico; Alanina Transaminase/uso terapêutico; Inibidores da Angiogênese/uso terapêutico; Anticorpos Monoclonais Humanizados; Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos; Aspartato Aminotransferases/uso terapêutico; Humanos; Inibidores de Checkpoint Imunológico/efeitos adversos; Inibidores de Poli(ADP-Ribose) Polimerases/uso terapêutico; Piridinas; Ribose/uso terapêutico; Neoplasias de Mama Triplo Negativas/tratamento farmacológico; Neoplasias de Mama Triplo Negativas/patologia; Fator A de Crescimento do Endotélio Vascular/uso terapêutico; Receptor 2 de Fatores de Crescimento do Endotélio Vascular/uso terapêutico; gama-Glutamiltransferase/uso terapêutico

Palavras-chave

Apatinib; Camrelizumab; Fuzuloparib; Immunotherapy; PARP; PD-1; TNBC; Triple-negative breast cancer; VEGFR

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias de Mama Triplo Negativas Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google